Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17791
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNg Tang Fui, Mark-
dc.contributor.authorHoermann, Rudolf-
dc.contributor.authorPrendergast, Luke A-
dc.contributor.authorZajac, Jeffrey D-
dc.contributor.authorGrossmann, Mathis-
dc.date2016-12-28-
dc.date.accessioned2018-05-28T06:13:45Z-
dc.date.available2018-05-28T06:13:45Z-
dc.date.issued2017-03-
dc.identifier.citationInternational Journal of Obesity 2017; 41(3): 420-426en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17791-
dc.description.abstractObese men commonly have reductions in circulating testosterone and report symptoms consistent with androgen deficiency. We hypothesized that testosterone treatment improves constitutional and sexual symptoms over and above the effects of weight loss alone. We conducted a pre-specified analysis of a randomized double-blind, placebo-controlled trial at a tertiary referral center. About 100 obese men (body mass index (BMI)⩾30 kg m-2) with a repeated total testosterone level ⩽12 nmol l-1 and a median age of 53 years (interquartile range 47-60) receiving 10 weeks of a very-low-energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of intramuscular testosterone undecanoate (n=49, cases) or matching placebo (n=51, controls). Pre-specified outcomes were the between-group differences in Aging Male Symptoms scale (AMS) and international index of erectile function (IIEF-5) questionnaires. Eighty-two men completed the study. At study end, cases showed significant symptomatic improvement in AMS score, compared with controls, and improvement was more marked in men with more severe baseline symptoms (mean adjusted difference (MAD) per unit of change in AMS score -0.34 (95% confidence interval (CI) -0.65, -0.02), P=0.04). This corresponds to improvements of 11% and 20% from baseline scores of 40 and 60, respectively, with higher scores denoting more severe symptoms. Men with erectile dysfunction (IIEF-5⩽20) had improved erectile function with testosterone treatment. Cases and controls lost the same weight after VLED (testosterone -12.0 kg; placebo -13.5 kg, P=0.40) and maintained this at study end (testosterone -11.4 kg; placebo -10.9 kg, P=0.80). The improvement in AMS following VLED was not different between the groups (-0.05 (95% CI -0.28, 0.17), P=0.65). In otherwise healthy obese men with mild to moderate symptoms and modest reductions in testosterone levels, testosterone treatment improved androgen deficiency symptoms over and above the improvement associated with weight loss alone, and more severely symptomatic men achieved a greater benefit.en_US
dc.language.isoeng-
dc.titleSymptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternational Journal of Obesity (2005)en_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationDepartment of Mathematics and Statistics, La Trobe University, Bundoora, Victoria, Australiaen_US
dc.identifier.doi10.1038/ijo.2016.242en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8261-3457en_US
dc.identifier.pubmedid28028318-
dc.type.austinJournal Article-
dc.type.austinRandomized Controlled Trial-
dc.type.austinResearch Support, Non-U.S. Gov't-
local.name.researcherGrossmann, Mathis
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.